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Abstract
In vitro air–liquid interface (ALI) cell culture models can potentially be used to assess inhalation toxicology end-
points and are usually considered, in terms of relevancy, between classic (i.e., submerged) in vitro models and
animal-based models. In some situations that need to be clearly defined, ALI methods may represent a comple-
ment or an alternative option to in vivo experimentations or classic in vitro methods. However, it is clear that
many different approaches exist and that only very limited validation studies have been carried out to date.
This means comparison of data from different methods is difficult and available methods are currently not suit-
able for use in regulatory assessments. This is despite inhalation toxicology being a priority area for many gov-
ernmental organizations. In this setting, a 1-day workshop on ALI in vitro models for respiratory toxicology
research was organized in Paris in March 2016 to assess the situation and to discuss what might be possible
in terms of validation studies. The workshop was attended by major parties in Europe and brought together
more than 60 representatives from various academic, commercial, and regulatory organizations. Following ple-
nary, oral, and poster presentations, an expert panel was convened to lead a discussion on possible approaches to
validation studies for ALI inhalation models. A series of recommendations were made and the outcomes of the
workshop are reported.
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Introduction
A ir–liquid interface (ALI) in vitro lung cell modelscan be used to investigate physiological and pathophys-
iological responses of the respiratory tract, molecular events,
and modes of action and interaction of different cell types.
Potentially, they mimic more closely the in vivo situation
of cells in the respiratory tract, namely, being apically ex-
posed to air. Such ALI models focus on particular anatomical
regions of the lung or particular molecular pathways and aim
to model processes that are relevant in vivo.1,2
Interest in such models has grown since they are under
development to provide information on the effects of xe-
nobiotics in lungs and potentially downstream systemic con-
sequences that may relate to health and disease endpoints.
Such observed effects may be relevant for the in vivo situa-
tion and the models may therefore also have the potential to
reduce the numbers of animals used in experimental toxicol-
ogy and risk/hazard assessments required in many jurisdic-
tions especially if international validation (via The European
Union Reference Laboratory for Alternatives to Animal Test-
ing, i.e., EURL ECVAM) could be achieved. Animals have
routinely been used for such assessments simply because no
in vitro methods have ever been validated to sufficient levels.
In that respect, animal usage in this domain is still widely seen
as the only option available. However, anatomical differences
between rodent and human lungs are significant, which has
strong implications for the deposition rates and localizations
of all particulates making extrapolation from animals to hu-
mans difficult. There is a strong societal and legal support to
reduce, refine, and replace the use of animals (3Rs) and this
in turn is driving the development of so-called alternative
methods—the most promising being ALI approaches in the
domain of inhalation toxicology.
Verification or validation of alternative methods is there-
fore seen as key to progress in the field of inhalation toxicol-
ogy. To this end, data from different in vitro experimental
approaches need to be compared and contrasted with in vivo
studies.3 Unfortunately, at the moment, no alternative method
that specifically uses respiratory tract cells cultured under ALI
conditions and exposed via air is validated by EURL ECVAM
and there is a clear lack of harmonization/standardization in
the way such methods are currently used. This is a major prob-
lem for hazard and risk assessment as the reliability and repro-
ducibility of results and hence the conclusions that can be
drawn from such experiments are at present rather limited.
Against this background, a workshop on ALI in vitro mod-
els for respiratory toxicology research was organized in Paris
on March 21, 2016, to bring together the major parties in
Europe with a stake in the use of ALI in vitro lung cell mod-
els. The workshop was organized under the auspices of
NanoReg2, a European Union (EU)-funded Horizon 2020 re-
search and innovation program in conjunction with INERIS,
France, and TNO, The Netherlands.
In total, around 60 scientists from academia, industry, and
regulatory bodies attended the 1-day workshop. The main
aims were to discuss the current state-of-the-art exchange ex-
perience in terms of practical aspects and to discuss how to
move forward with the air–liquid approaches with regard
to future implementation in a regulatory context. The work-
shop consisted of a series of plenary lectures, short oral pre-
sentations, poster presentations, and finally, a discussion led
by a panel of experts. This article documents the outcomes of
the workshop and provides a series of recommendations for
the future development of the methods either in the main
text or in the Supplementary Data (Supplementary Data are
available online at www.liebertpub.com/aivt).
After presenting background information, the article deals
with the current knowledge and practices of ALI approaches,
in terms of atmosphere generation, exposure principles, and
cell models available. Then, the outcomes of the expert panel
discussion are presented, highlighting the validation process
and the challenges to overcome the validation of ALI tech-
niques. Finally, several recommendations are presented to
implement the validation process.
Background
Respiratory health and disease related to ambient air pol-
lution are a major concern worldwide.4 Apart from air pollu-
tion, numerous chemicals and particles need to be assessed in
the context of the EU REACH (registration, evaluation,
authorisation, and restriction of chemicals) regulation for
pulmonary toxicity. Health effects due to inhalation of sub-
stances are therefore of considerable interest to many and
form the basis for the use and development of in vitro models
of the respiratory tract. As well as studying the efficacy of new
pharmaceutically active compounds,5 a major use of the mod-
els is to examine the potentially toxic effects of different types
of compounds ranging from chemicals to (nano)particles,
such as Ag,6 SiO2,
7 CeO2, and TiO2,
8 multiwall carbon
nanotubes,9 or complex combustion-derived aerosols.10–12
Many different models have been used ranging from
in vivo animal experiments to in vitro models using lung
cells.13 In the latter case, many different types of exposure
scenarios have been used and indeed the cells used can be
animal or human derived. Despite differences between the
various models, the core ambition is to model what likely
happens in vivo as closely as possible with in vitro techniques.
ALI in vitro inhalation models are increasingly being used
in research and this comes with some advantages, not least
that their use has the potential to reduce the numbers of an-
imals used in research because they are more realistic as
they mimic more closely the pulmonary region than classic
(i.e., submerged) in vitro methods. Their use may also pro-
vide better information on in vivo processes in humans and
allow investigations into mechanisms that occur in humans
(some of which might differ or do not exist in animal models
due to variations in physiology).14
Their increasing use in EU-funded projects (e.g., FUTURE-
NANONEEDS, npSCOPE, SPOTVIEW, NANOREG,
NANOREG2, PneumoNP) highlights the levels of interest
in ALI models and potential realms of application. While
their increased use is starting to provide novel information
on endpoints and potential mechanisms, stakeholders at the
EU level have raised questions about levels of validation
and standardization of the methods and concerns about
how much information coming from the projects in particu-
lar can actually be compared. On the basis of this, the sug-
gestion was made by one particular stakeholder, to pull
together relevant experts to discuss whether and how such
validation and standardization studies could be performed.
The workshop in Paris in March 2016 was the result and
had the specific aim of starting a process of alignment
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among stakeholders toward the validation of in vitro ALI in-
halation lung cell models combined with the air–liquid expo-
sure system to aerosolize a substance/chemical of interest.
ALI Exposure: Recent Advances and Challenges
Generation of exposure atmospheres
for biological applications
General considerations. The purpose of delivery of
inhaled substances to cells via an ALI is to mimic the phys-
iological processes of mass transfer to and within the epithe-
lial layers of the lung.
For particles, the mass transfer to the surfaces is deter-
mined by directional volume forces such as gravity, thermo-
phoretic and electrical forces, as well as diffusional motion.
The transfer rates are strongly dependent on the aerodynamic
size of the particles.
The transport of vapors to the surfaces is primarily con-
trolled by the interaction of the substance with the liquid lin-
ing layer/cell surface. This usually occurs via dissolution and
reactivity processes.
To be comparable with real-life exposure, the composition
of the exposure atmosphere in the test setup should be similar
to what it is in real life regarding particle size distribution
and chemical composition. The determination of adminis-
tered dose is required for the interpretation and classification
of measured biological effects. For particles, the dose can be
measured in a reference membrane insert either equipped
with a quartz crystal balance or by chemical and fluorescence
analysis of the material recovered from the insert.15 Modeling
can also contribute to dose determination (see e.g., Refs.16,17).
Methods for the generation of exposure atmospheres to be
tested with cell-based in vitro methods can be set up for
gases, vapors, complex atmospheres such as from diesel en-
gines, wood stoves, or others, or from pure test materials.
Methods of aerosol generation from pure test materi-
als. There are three different ways to generate aerosols: for-
mation of aerosols by dispersion of liquids, generation of dry
solid particles by dispersion of powders or ablation from
solid bulk materials, or particle formation by gas to particle
formation (i.e., nucleation and subsequent growth by con-
densation and coagulation).18–21
Liquids. Liquid drops can be generated using the inher-
ent instabilities of filaments and jets, which are formed by
application of hydrodynamic forces applied to the liquid in
various nozzle configurations.22 Frequently, air-assisted neb-
ulizers are used to generate aerosols for medical application.
The liquid mass flux is either established by the Venturi prin-
ciple or it is fed into the dispersion unit by a peristaltic pump
allowing for independent control of the liquid mass flow. The
liquid is disintegrated by interaction with high-speed airflow
in the zone where the liquid flow and the air flow are mixed.
Liquid dispersion can also be facilitated without airflow at
all, either by using ultrasonic energy applied to a liquid sur-
face, by pumping the liquid through an oscillating perforated
mesh, or by using electrical forces. The underlying physical
principles of droplet formation are the instability of capillary
surface waves formed when the liquid is agitated by ultra-
sonic waves and the natural Rayleigh instabilities of the
jets formed in the perforated mesh system. When a fluid jet
is highly charged, Coulombic repulsion leads to droplet for-
mation. This method is called electrospraying.23,24
Depending on the process parameters, mass median aero-
dynamic droplet diameters in the range between 2 and 10 lm
can be achieved using mechanical generation methods,25
whereas electrospray generation results in submicron drop-
lets (<1 lm). The liquid generation method can be applied
to pure liquids as well as to solutions of nonvolatile com-
pounds or suspensions of nanoparticles. This offers the pos-
sibility to further reduce the aerosol size by evaporation of
the solvent and will result in droplet shrinkage until a dry
aerosol state is reached where it is composed of the nonvol-
atile compound only. This method is particularly interesting
when nanoaerosols with a low degree of agglomeration have
to be produced, which can be achieved by electrospraying
dispersions of low concentrations of solid material (as
shown by Fu et al.23). Here the initial droplets are already
in the 100 nm range. After evaporation of the water, the
dry aerosol particles can be as small as several nanometers.
Powders and bulk material. Generation of aerosols from
dry powders is somewhat similar to nebulization of liquids in
that it requires a feeding technology to establish the powder
mass flow and the supply of external energy for its deag-
glomeration. Powder feeding can be metered by various
mechanisms that include spiral screws, groves, or holes in
a rotating disk, or just gravitational forces. Dispersion is
facilitated by stationary or transient high air speeds,26–29
scraping mechanisms, or mutual collisions between powder
agglomerates such as jet mills, fluidized beds,30,31 externally
excited fluidized beds (vortex shaker32), or collisions of ag-
glomerates with surfaces (fluidized bed with dispersion
balls). Methods based on acoustic excitations of a powder
layer are used particularly for the generation of airborne fi-
brous materials such as carbon nanotubes.33
Aerosols can also be generated directly from solid bulk ma-
terials by electrical spark ablation or laser ablation. In the
spark generator, molecules or clusters are detached from the
surfaces of solid bodies by electrical sparks established be-
tween two electrodes made of the solid compound under con-
sideration. Therefore, this method is limited to conductive
materials. Laser ablation requires the absorption of light by
the compounds. The spark generator is widely applied in tox-
icity studies particularly in view of elucidating the mechanistic
aspects of any biological effects.34,35 Laser ablation is a well-
suited method to produce nanoparticles directly in the aqueous
environment. This suspension can then be aerosolized using
the methods described in the previous section.36
Gas to particle conversion. A completely different route
for (nano-) aerosol generation is gas to particle conversion.
Combustion-generated aerosols are formed in this way. Typ-
ically, there are gaseous precursors at elevated temperatures,
which form condensable species either just by cooling or by
chemical reaction. Particles then grow by heterogeneous con-
densation and/or coagulation. By properly quenching the
processes, particle distributions can be limited to the ultrafine
size regime. Pure condensational growth leads to nearly
monodisperse particles, whereas coagulation results in
wider particle size distributions.
Gold particles formed by gas to particle conversion, which
then interact with various biological fluids, have previously
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been described.37 A method to generate zinc oxide particles
in a flame reactor has also been described, and in this case it
was demonstrated that using the submerged and ALI routes
of cell exposure did result in different (toxicological) end-
points being reached.38 A method has also been developed
to examine inhalational exposure to bitumen fumes based
on the evaporation and recondensation of fume condensates
sampled from bitumen storage tanks.39 This approach effec-
tively allows one to exactly mimic real fume exposure at spe-
cific workplaces and to apply the resulting aerosol in both
in vivo and in vitro experiments.
ALI exposure units have to be properly interfaced with the
generation method. This can be done by placing a mixing/
equilibration volume between generation and exposure sys-
tem. The volume flows of the aerosol generation system
can be decoupled from the airflow used for cell exposure.
A feedback control system can be helpful to keep the concen-
tration at the desired level.
Exposure of cell-based in vitro systems to study biological
effects of airborne compounds
General principles/background on in vitro airborne expo-
sure. The exposure itself has in principle one simple but
major task: to establish an effective contact between the bi-
ological test system used, such as cells,40 tissue, or ex vivo
material (e.g., precision-cut lung slices41), and the exposure
atmosphere. This includes an intensive and defined contact
with the gas phase as well as with the particle phase of air-
borne material and to establish dose metrics as a fundamental
requirement of any successful in vitro testing.
Moreover, any artificial exposure effects on the exposed
biological material have to be avoided. Since the original en-
vironment of any biological test system is the liquid phase
whereas the original environment of the exposure atmo-
sphere is by definition the gas phase, there are mainly three
possible ways to go for a combination:
(1) by transferring the test material from the gas phase to
the liquid phase,
(2) by transferring the biological test system to the gas
phase for a time intermittently to (1), above, or,
(3) by transferring the biological test system to the gas
phase continuously.
In reality, these three strategies have been applied during pre-
vious decades to establish cell-based in vitro methods for test-
ing airborne material. Already more than 40 years ago, cell
suspensions from alveolar macrophages were used to study
the biological effect of chemical gases such as nitrogen diox-
ide by bubbling the gas through the culture medium.42
This strategy is still used for setting up new methods such
as the hanging-drop exposure model.43 Here human lung
cells (A549 cell line) are used in suspension culture to then
be exposed to gaseous chemicals inside a small drop under
static exposure conditions in a closed vessel. Strategies cor-
responding to (2) (above) are represented by intermittent ex-
posures of cells or ex vivo material to the atmosphere using
half-filled roller bottles44,45 or tilted, rotating multiwell plates.46
With respect to the key feature of biological relevance, it
is possible that the cellular organization of the biological cell
or tissue material used in such approaches may be relatively
far away from the in vivo situation in the human lung.
Also, with respect to exposure relevance, it has to be taken
into account that the presence of culture medium as the com-
pound of primary contact with the test material will result in
a relatively low efficiency of contact between the test atmo-
sphere and the cells.47 Moreover, it will lead to physico-
chemical modifications of the airborne test material. In the
simplest case this will lead to a change in particle sizes.
However, depending on the test material, it may also lead
to chemical changes in the test atmosphere in case of chem-
ically reactive components in a complex mixture.48
Also, exact dose can be hard to accurately measure due to
unknown physicochemical properties and kinetics of the test
material in specific culture media. As a result, these strate-
gies do not represent the primary route of exposure of the
inner biological surfaces of the human respiratory system
to inhaled atmospheres.
ALI exposure. Contrasting to this, cultures lifted to the
ALI42 seem to offer the basis for a perfect translation of
the biological in vivo organization of the respiratory system
to in vitro. By culturing tissue, cells, or ex vivo material on
microporous membranes while feeding and humidifying
them only from the basal side, a biological barrier model is
set up separating the inhaled air/exposure atmosphere com-
partment from a blood/liquid/culture medium compartment
in a construction that is highly relevant to the in vivo setting.
With respect to exposure relevance, ALI models offer
unique properties.
Due to the exposure situation of the models that expose the
biological system continuously to the atmosphere, the expo-
sure agent does not interact with cell culture medium, which,
especially for particles, can result in changes of the proper-
ties (dissolution, agglomeration).
As a result, it is possible to conduct exposure approaches
from real-life atmospheres by taking the exposure setup, in-
cluding the biological test system to the source of the expo-
sure atmosphere.49 This is also the experimental basis to
consider relevant factors such as physicochemical properties
of the test atmosphere, different experimental methods for
generation and characterization of test aerosols and to estab-
lish an unhindered, defined contact between the biologi-
cal test system and the test material in the airborne state.
Hence, also from the point of exposure relevance, ALI mod-
els exhibit a large range of possibilities.
The ALI exposure situation described above could be seen
as an ‘‘ALI microclimate’’ condition. Two main mass trans-
ports control this state: the mass flow of liquid culture media
through the membrane toward the cells and the fluid flow
necessary to transport the airborne test material to the surface
of the biological test system.
A range of setup specific factors can then have a large im-
pact on this scenario. Cell-specific characteristics (e.g., the
formation of cell/cell contacts that provide epithelial barrier
activity), pore sizes, and pore densities of the membrane, hy-
drophobicity of the membrane surface, flow rate of the gas
flux, humidification of the test atmosphere, pressures of cul-
ture media and test atmosphere, characteristics of the culture
media (e.g., osmolarity, viscosity) and more are all examples.
By appropriately setting up these parameters, it is possible
to generate an ‘‘in control’’ state, where high exposure effi-
ciencies and a good preservation of cellular viability can be
expected at the same time. However, any physical coverage
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of cells has to be taken into account as an important factor of
influence on the system. Types of cell coverage may include
the intended presence of mucus, epithelial lining fluid, or a
surfactant, and these are usually included to increase the
relevance of the biological model. Cell coverage may also
occur in an unintended manner from, for example, an in-
creased flux of culture media through the membrane as a re-
sult of the chosen membrane type and pore size.
In any case, cell coverage by fluids will have a large im-
pact on the sensitivity and relevance of the model, since a
physicochemical cross talk between the coverage and the air-
borne test material will now take place. Hence, diffusion ki-
netics and reaction kinetics will be limiting for the contact of
cells and the gas/aerosol phase. As an example, it is well
known48 that only very small coverages of biological mate-
rials by lining fluids prevent contact of ozone with cells
and that this is due to the extremely fast reaction kinetics
of ozone. This can also be shown experimentally through
variation of cell coverage by culture media during ALI
exposure—there is a clear change in dose/response of cells
toward ozone.47 Hence, a definition of the specific ALI expo-
sure state is critically needed for specific exposure setups, es-
pecially when setups using different biological test systems
are to be compared with respect to the outcome of a testing
scenario. It is especially important to consider the epithelial
barrier activity of the culture used, to prevent medium leak-
age to the apical surface of the cultured cell layer, which may
affect the outcome of the exposure.
The flow alignment of ALI exposure setups is usually one
of two types (Fig. 1). The incubator/box-type setup50–52
includes the positioning of cultures inside a box, which may
also be a cell culture incubator. The box is then filled or rinsed
with the test atmosphere leading to a horizontal exposure flow
above the inserts of the cultures. A more sophisticated setup is
represented by the stagnation flow setup53,54 where the expo-
sure flow is directed toward the ALI surface. Using this flow
alignment, an individual exposure of single cultures can be
achieved. Moreover, an optimization of fluid dynamics is pos-
sible leading to a better-defined dosimetry and a higher expo-
sure efficiency. Exposure setups based on these basic ALI
flow alignments are commercially available and can be
found in the literature or as in-house solutions of a number
of working groups. Hence, for example, TSE Systems (Bad
Homburg, Germany) is offering an exposure system based
on a box, while others55,56 have published respective setups
based on box designs. The same is true for the basic stagnation
flow setup, where in-house versions57 and commercial solu-
tions are available (e.g., Vitrocell, Waldkirch, Germany;
CULTEX, Hannover, Germany, among others).
Using these basic exposure alignments, exposures of cells
to gases have been successfully conducted, and as a result, a
first small prevalidation study has been performed in Ger-
many.58 There was good inter- and intralaboratory reproduc-
ibility, and a relevance of the model using A549 cells could
be shown for acute toxicity screening of chemical gases in
terms of acting as a first predictive model.
Particle deposition. The exposure scenario becomes
more complicated when particles are involved during expo-
sure to aerosols. Particle deposition in the lung in vivo is a
complex process and strongly affected by physicochemical
properties of the test aerosol (e.g., particle characteristics
such as size, shape, density, and solvability can all play a
role). This leads to particle deposition rates that differ
according to properties, and that also vary according to the
lung region being studied. Such behavior can be estimated
with mathematical models such as the ICRP (International
Commission on Radiological Protection)59 or the MPPD
(Multi-Path Particle Dosimetry) models.60
As a consequence of this, certain test aerosols, especially
when composed of a mixture of different compounds, do not
have an equal relevance for all lung regions. Hence, the
translation of the in vivo scenario to an appropriate in vitro
modeling scenario has not been fully addressed in many
cases. Strategies to solve such issues can include aiming
for a maximum deposition efficiency within the in vitro
model independent of the particulate size under investiga-
tion. Alternatively, a specific deposition efficiency can be de-
fined according to a selected localization in the lung or an
in vivo curve-like deposition efficiency or others. Especially
with regard to any standardization or harmonization pro-
jects, these basic strategies are of fundamental importance
to achieve comparable exposure and dosimetry characteris-
tics using different experimental approaches.
For individual experiments involving the in vitro exposure
of cells to aerosols, the most important factor governing
FIG. 1. Main ALI exposure
setups. (a) ‘‘Incubator/box-
type’’ setup featuring a hori-
zontal flow, a ‘‘smooth’’ cell
exposure, and often using
standard commercial culture
plates. It results in a con-
joined exposure of cultures
with less defined fluid dy-
namics. (b) ‘‘Stagnation point
flow’’ setup featuring indi-
vidual exposure of single
cultures, offering optimized
fluid dynamics and an effec-
tive cell to gas contact al-
though it usually calls for
custom-made constructions
and more sophisticated set-
ups. ALI, air–liquid interface.
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outcomes is the deposition efficiency of the aerosols onto the
surface of cells. Its impact on outcomes can be limited, how-
ever, using basic flow alignments that alter sedimentation
and diffusion mechanisms. Such approaches are available
in many of the systems mentioned above. For example, it
has been shown that the deposition efficiency of these sys-
tems is in the range of 2% for particle sizes smaller than
1000 nm.54,61 Hence, 98% of the particles conducted over
the cellular surface during exposure are just lost. On that
basis, it has been calculated16 what exposure time would
be needed in an experimental approach, where the in vivo
lowest observed adverse effect level determined in sub-
merged experiments from silicon dioxide of 15.6 lg/cm2
would be established during an in vitro ALI exposure.62
Using the given experimental conditions and 100 nm SiO2
particles, they calculated an exposure period of about
400 hours would be needed.16 Thus, comparisons of most
in vitro studies using submerged cultures and extremely
high doses of particles with ALI experiments without en-
hanced deposition efficiency are not possible. Yet, in vivo
on inhalation particle load is significantly lower and there-
fore much more similar to the ALI methods.2
Experimental approaches to improve this situation are
mainly based on three principles: (1) electrostatic deposition,
(2) droplet deposition, or (3) thermophoresis (also known as
thermal precipitation) (Fig. 2). Electrostatic deposition in-
volves the biological test system being exposed during align-
ment in an electrical field of usually 1000 V or higher.63–65
FIG. 2. Main methods to improve particle deposition. (a) Electrostatic deposition on ALI cells to enhance particle depo-
sition from aerosols. Aerosol particles are charged unipolar (left) or bipolar (right) and forced onto the cellular surface in an
electric field with a constant (unipolar setup) or frequently changed (bipolar setup) polarity. (b) Droplet deposition on ALI
cells. Particles are suspended in aerosol droplets to increase the particle size. Aerosol droplets are deposited on the cellular
surface by gravitational forces. Depending on experimental conditions, this procedure may be enhanced by cloud movement
effects of highly concentrated aerosols. (c) Enhancement of native particle deposition on ALI cells by thermophoresis. A ther-
mal gradient of 15C–20C is applied between the cells and the aerosol, leading to a higher velocity of molecules in the aero-
sol gas at the warmer side. By this thermophoretic effect, aerosol particles are forced to the cellular surfaces of ALI cells.
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Using a unipolar setup, the aerosol is positively or negatively
charged and the aerosol particles are forced to the surface of
the exposed cells by electrostatic forces. Also, uncharged
aerosols have been used for this strategy by using the natural
charge of aerosols.66 In a modification of this basic electro-
static approach, bimodal charging of the aerosol has been
introduced in combination with a continuously changing
polarity of the electrical field around the exposed cells.67,68
Following this approach, a more balanced deposition of pos-
itively and negatively charged particles was pursued with the
aim being an electrically neutral result in terms of the expo-
sure process. The main advantage of setups based on electro-
static deposition is high deposition yields, which in theory
can reach up to 100%. However, due to practical limitations
and adaption of the physical principle to biological expo-
sures, deposition rates reported for these systems were
between 4% (130 nm silicon dioxide66) and 47% (500 nm
polystyrene latex spheres63). Common concerns regarding
electrostatic deposition strategies include possible adverse
effects on the exposed cells due to high electrical fields
and the separation of electrical charge of ionic components
in culture media may also be an issue that has to be evalu-
ated. For example, in A549 lung epithelial cells at a voltage
of 1 kV, no adverse effects were observed using a basic
(but insensitive) parameter for cell toxicity (lactate dehy-
drogenase release).7 Clearly, more cell systems need to be
addressed in the future to draw firm conclusions on the ef-
fects of strong electrical fields. Also, under debate are possi-
ble effects of changes introduced to aerosol particles through
electrical charging and the consequent changes in biological
effects that might result. For example, it was observed that
especially with respect to smaller particles, a change of elec-
trical properties of particles might change their behavior in
cellular uptake and toxicology.69,70
As an alternative to electrical deposition setups, droplet
deposition has previously been reported.6,71,72 Here the test
material is suspended or dissolved in a liquid medium and
applied as a droplet aerosol in a small chamber through neb-
ulization (via a commonly used nebulizer system; Aeroneb;
Aerogen). The cloud movement effect resulted in a highly ef-
fective deposition rate of about 56%. However, this approach
cannot be applied to gases, sampling aerosols, or testing par-
ticles maintaining their dry physicochemical characteristics.
Being based on droplet application, it has a clearly different
objective than the other approaches for improvement of par-
ticle deposition from aerosols during ALI exposure.
The most recently applied approach for particle deposi-
tion improvements involves the thermophoretic effect (also
known as thermal precipitation). In an unusual alignment
of cells cultured on the bottom side of culture inserts, a
setup has been established73 where particles are forced from
horizontal aerosol flows onto the surface of cells during
exposure. The thermal precipitation approach has some funda-
mental advantages. First, by principle, the exposed biological
material should not be affected by the physical effect used,
since a thermal gradient is used with the standard culturing
temperature of the cells (35C–37C) on its colder side. Sec-
ond, thermal gradients applied in the system were in the range
of 15C–20C higher than the cell culture temperature. Thus,
nearly no pretreatment of the test aerosol is needed, which
makes it very applicable from the practical perspective and
since the temperature of the aerosol can be applied very
shortly before contacting the cells, no significant changes in
physicochemical properties of the aerosol are expected.
Thermophoresis was also used in a further development
where it was combined with a stagnation flow arrangement
and a consequent use of consumable standard microplates
throughout the exposure experiment.40 As a result, this expo-
sure system does not require any change of the cellular envi-
ronment before or after single or repeated exposure and
offers multiple test groups on one plate in a very compact de-
sign. Moreover, it has completely separated compartments
for exposure atmosphere flow and culture media. Hence,
only the relevant route of exposure from the test atmosphere
toward the cells is enabled, whereas any second route of ex-
posure via the contact of the exposure atmosphere to the cul-
ture media is completely prevented.
Overview of cellular models used at the ALI
For the purposes of testing inhalation toxicology endpoints,
animal-based studies are limited in a variety of ways. These in-
clude ethical questions relating to animal experiments, their
high costs, and questions about their biological relevance as ro-
dent and human airways are anatomically very different.74 This
particular aspect means the resulting air flow rates and air
speed in the airways of animals differ from those of humans
and this means there will likely be differences in the deposition
of particles. Taken together, alternative methods that can re-
place, refine, and reduce animal-based experiments are very
much needed, not least from the perspective of better repre-
senting biological processes that actually happen in humans.
This is despite many regulatory assessments currently requir-
ing animal testing in various domains.
Relevance to the in vivo situation. The trachea of a mouse
has an internal diameter of*1.5 mm and is lined by a pseu-
dostratified epithelium with about 55% ciliated cells, 30%
basal cells, some secretory cells, and sparse neuroendocrine
cells. In the rat trachea there are more ciliated cells in the ep-
ithelium.75 In the mouse, there are six to eight generations of
intrapulmonar branches with a stereotypical branching
pattern.76 The terminal bronchioles leading into the bron-
chioalveolar duct have less ciliated cells (*26%) compared
with more proximal airways. In contrast, the average human
trachea has an internal diameter of*12 mm. There are more
generations of intrapulmonary branches than in the mouse,
and cartilage plates and smooth muscle surround the intra-
pulmonary airways deep into the lung. A pseudostratified ep-
ithelium built with basal cells and ciliated and secretory
(mucus-producing goblet cells and club cells) cells lines
these airways, whereas intrapulmonary airways in mice are
characterized by the abundance of club cells.
In terms of anatomical features of the respiratory tract, po-
tential regions of interest include the nasal and oral cavities,
larynx, trachea, and alveolar region and commercial solu-
tions to model these are already available for all these re-
gions except for the alveolar region.
A key requirement for any alternative method is the rele-
vance and comparability with the anatomical feature being
modeled. For respiratory health, this means relevance in re-
lation to the respiratory tract in humans. As already men-
tioned, there are key differences in the respiratory anatomy
of humans and mice/rats, which means interpreting data
from cell models derived from rodents in the human context
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is fraught with difficulty. A key principle here therefore is
that, if possible, human-derived cells should be used for
modeling human-related respiratory issues and that rodent
based-cells should be avoided.
ALI systems therefore have the potential to conceptually
provide relevant data since it is possible to construct them
from human-derived cells and create modeling scenarios
that are close to what might occur in vivo. For example, dos-
ing can be exactly controlled and measured and particles
or aerosols are not altered by contact with cell culture as
would happen in a submerged model. Therefore, exposure
of cells at the ALI is highly relevant for the physiological
in vivo situation. In comparison to in vivo modeling with an-
imals, dosing with ALI systems can also be controlled in
much more accurate ways.
Respiratory cellular models. In terms of pulmonary mod-
els, a wide choice is available in terms of complexity (Fig. 3).
The standard submerged two-dimensional cell culture is a
simple procedure that is low cost and amenable to high-
throughput processing. The complexity of in vitro models
can then increase with the addition of characteristics that in-
creasingly match the reality seen in humans. Examples of
such models include mixed cultures (i.e., two or more cell
types in one well) and three-dimensional (3D) cultures.
Options do exist for using rodents and finally even human
ex vivo tissue slices. While costs increase in line with the
complexity of models, the physiological relevance also in-
creases and this means the quality of data obtainable from
more complex models is significantly improved.
The standard submerged cell culture cultivates the cells
submerged in culture medium, which means it does not re-
flect the reality of the lung where cells are exposed to air.
This means relevant cell culture modeling relating to the
lungs and respiratory tract usually require an ALI if they
are to have any relevance to reality in humans.
The development of ALI has been driven by groups inter-
ested in the biological effects of particles, as particles and
nanoparticles react with proteins and/or lipids present in
cell culture medium as this is the case for submerged cul-
tures. This means that the biological activities of (nano) par-
ticles may change77,78 resulting in a corona formation, which
in turn results in changed toxicity and altered cellular uptake.
In short, a liquid interface will likely result in effects that in
reality do not occur when cells from the pulmonary tract are
placed in their more biologically relevant environment—
namely at the ALI. One has, however, to keep in mind that
the lung cells are covered with an aqueous lining and a
mucus or surfactant lipid layer, which also can result in a
protein corona formation of (nano)particles.79
Many relevant cell types have been investigated in combi-
nation with ALI. This has included primary cells,80 single
cell line cultures,81 3D,82,83 and cocultures84 tissue slices,85
and recently, several publications have emerged that have
used organ-on-a-chip approaches.86 Considering primary
cells, inter- and intra-individual variation can be consider-
able87 in terms of donor source.
The application of an ALI in cell culture models is wide-
spread according to published literature. Examples include
the use of skin cells,88 corneal cells from the eye,88 cells
from the gingival epithelial mucosa,89 or various cell types
from the respiratory tract,90–92 and also combinations of cell
types (e.g., skin with melanocytes, epithelial lung cells,
and immune cells).10,93 Sources of cells have included human,
chicken, and rodents.88 Applications, meanwhile, have in-
cluded the effects of (nano)particles,93 viruses,94 and bacte-
ria,95 and also various chemicals,96 pharmaceuticals,97 and
tobacco products.82,89,98
Many cell types from the pulmonary system have been
used in combination with an ALI. For the epithelial cells
of the airways, there are a number of cell lines available.
These include Calu-3,99–101 16HBE14o,102–104 and BEAS-
2B.105–108 Alveolar epithelial cells can be modeled with A549
cells although they miss functioning tight junctions.109–111
Immortalized human alveolar type 2 cells with alveolar
type 1 phenotype can also be used as a model.112
In terms of 3D cultures, there are many examples of pos-
sible models for the respiratory tract. These include primary
endothelial and epithelial cells,113,114 a triple cell coculture
model (comprising epithelial cells, primary macrophages,
and dendritic cells115–117), and a tetraculture model (com-
prising epithelial and endothelial cells, macrophages, and
mast cells118,119). Commercial solutions are also available
that model 3D human reconstructed bronchial airways
FIG. 3. Respiratory models
available from simple to
complex. Costs and also
physiological relevance in-
crease in line with the com-
plexity of models.
8 LACROIX ET AL.
(Epithelix and MatTek are examples). Airway cells are
obtained from patients undergoing surgical nasal polypec-
tomy or lung lobectomy. The epithelial cells are isolated
by enzymatic digestion. After amplification, the cells are
seeded directly on the microporous membrane of Transwell
inserts (e.g., 24-well format, Cat. No. 3470; Corning) and
grown in a commercially available defined airway culture
medium (e.g., EP04MM from Epithelix). Once confluent,
the cultures are switched to ALI. After 3–4 weeks of culture,
the epithelium becomes fully differentiated. As mentioned
earlier, an organ-on-a-chip approach has also been devel-
oped, including several cell types.120
A large in vitro toolbox is available from which specific
biological test systems can be set up. It includes cell lines,
primary cells,121 or reconstructed 3D models, and primary
ex vivo tissue such as precision-cut lung slices41 from differ-
ent species and different regions of the lung.
Cell systems (both single- and multi-cell cultures) and tis-
sue slices exposed to ALI conditions may also produce sur-
factant as shown for A549 cells exposed to air,122 which is
protective for the cells and will interact with the particles be-
fore contact with the cells underneath.
Comparisons between conventional and ALI cell cultures
show considerable differences in terms of biological readout.
For example, messenger RNA (mRNA) expression of a variety
of inflammatory mediators is considerably blunted when A549
cells are submerged and exposed to ZnO at the same concentra-
tion.123 Likewise, the release of IL-8 from A549 cells is con-
siderably higher when exposed to Aerosil200 and SiO2 and
submerged than when exposed via an ALI.7 More recently, a
coculture of A549 and THP-1 cells showed higher sensitivity
to poorly soluble nanomaterials (TiO2 and CeO2) when ex-
posed at the ALI compared to submerged exposure.8 Loret
et al. also highlighted the importance of considering the depo-
sition rates when comparing ALI to submerged exposure.
All exposure and culture models described so far operate
under ambient air pressure. However, this is not the case in
reality where air pressure varies according to breathing rate
and intensity. Although not high throughput, yet a system
does exist that allows the culture of alveolar cells under
breathing movement conditions.124 Recently, an organ-on-
a-chip solution was presented where the pressure can be al-
tered during culturing.86
Conclusion
ALI exposure systems, in whatever format, resemble
in vivo exposure conditions in a much more relevant way
than standard approaches to cell culture. However, there
are many factors to consider ensuring experimental condi-
tions remain relevant to what is likely to happen in reality.
While testing of pure gases is promising in well-established
basic exposure settings, the testing of aerosols requires more
extended experimental methods, involving also additional
physically engineered developments as a basis for relevance
and practicability. Cellular characteristics of the biological
material such as metabolic capacities, surfactant or mucus
production, tight junctions, and many other features are
also important to consider. Especially for routine testing,
commercial availability and costs may be issues. As a result,
the biological relevance of ALI models for testing of inhal-
able effects of airborne material seems currently unbeaten.
Experimental data also show that there are clear differ-
ences between observed effects when cells are exposed via
submerged conditions as opposed to ALI exposure. Indeed,
culture medium will react with particles and alter their phys-
icochemical and hence toxicological properties. Finally,
dose is highly controllable and measurable under ALI and
proper information on applied doses is important for under-
standing and interpreting any observed biological responses.
In short, ALI systems are more relevant to the in vivo situa-
tion than any other currently available in vitro approach
based on submerged cell cultures.
Short Oral Presentations and Poster Session:
Recent ALI Research Developments
A series of short presentations and a poster session fol-
lowed the plenary lectures. They highlighted the latest prog-
ress being made with ALI in vitro inhalation models.
Presentations covered topics such as the use of lung sur-
factant to predict acute lung toxicity of inhaled chemicals,
the comparison of ALI versus submerged exposures, the
use of organotypic EpiOral tissue cultures as a model for
inhalation studies, the presentation of new human in vitro
3D ALI models for small airways and lung cancer, the use
of 3D ALI in vitro lung model for assessing repeated expo-
sure to nanoparticles, and the use of ALI models to study ef-
fects of cigarette smoke and diesel exhaust exposures on
asthma and pulmonary disease(s).
During the poster session, a number of themes emerged,
including new automated approaches and the assessment of
effects of various chemicals (printer ink, hair-straightening
products, carbon nanotubes, waterproofing products, phar-
maceuticals, and e-cigarette vapors), using ALI approaches.
Methods to assess long-term exposures and low-dose expo-
sures were also reported.
Brief summaries of the poster and oral presentations are
given in Supplementary Data.
Validation: Expert Panel Discussion
While methods and core principles relating to ALI ap-
proaches are clearly developing, it is widely accepted in
the community of users that the approach is, at least in the-
ory, superior to submerged culturing of relevant cell types.
Key questions remain, however, in relation to validation.
At present, no in vitro methods relating to inhalation toxi-
cology are validated from a regulatory perspective and, in par-
ticular, no methods that use ALI approaches are validated.
This is despite ongoing work to develop the methods further.
A core aim of the workshop was to discuss this issue, to
assess what might be required in terms of validation and to
put in place a series of recommendations to start a process
of validation. From the outset it was recognized that valida-
tion of methods is important, but precisely what should be
validated, how validation should proceed, and who should
actually do the validating were key questions the participants
at the workshop hoped to start answering.
Overview of the validation process:
the EURL ECVAM protocol
For those interested in a full description of the validation
process and subsequent discussions, please refer to the Sup-
plementary Data relating to this topic.
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The process of validation usually refers to the process of
taking a method from the research and development phase,
through to the transfer of the method to application (this is
widely called prevalidation), maybe in industry or wider
research groups, and then to formal validation that in-
volves many different laboratories that essentially aim to
reach the same result regarding a set of test compounds or
outcomes.
Initially, prevalidation might involve simple repetition of
experiments and comparison of results. However, formal val-
idation may go much further and involve 10–100s of groups
of researchers all formally working to a set protocol and sub-
sequent full statistical analyses of the outcomes.
EURL ECVAM is the central EU organization coordinat-
ing validation of alternative methods to animal research. At
EURL ECVAM, the process for validation is divided into
four stages. There is an initial assessment of a submitted
method, actual validation studies, independent peer review,
and finally, the publication of an EURL ECVAM recommen-
dation on the validity of a method. This then may form the
input for the development of an OECD test guideline relating
to the method. Once that has been issued, it may be the case
that a method can then be used for regulatory purposes. A
final step may also include the development of an Interna-
tional Standards Organization (ISO) standard.
The initial assessment of a method by EURL ECVAM re-
volves around three criteria. These are (1) the scientific and
technical aspects of a method, (2) the regulatory relevance of
a method, and (3) the impact a method may have on 3Rs.
If a method satisfies the detailed criteria, it may then pro-
ceed to a validation study (it may not proceed to this stage if
either the method is judged to be incomplete in terms of the
criteria or alternatively that sufficient information/data on
validity were submitted initially and that the method can al-
ready be judged as valid).
The actual form of the validation study will depend on the
level of validation already achieved. Following the comple-
tion of the studies, an independent peer review is carried out
by EURL ECVAM’s Scientific Advisory Committee
(ESAC) who then issue an opinion. This forms the basis of
the final EURL ECVAM recommendation. The final stage
of validation is international recognition and regulatory ac-
ceptance, which can take many forms, including the develop-
ment of OECD test guidelines and ISO standards.
In conclusion, the overall message in relation to validation
is that ALI approaches for inhalation toxicology per se can
be put through a process of validation if the steps outlined are
followed and the time and budgets available to actually do it.
Validation of ALI techniques: challenges to overcome
While the theoretical and regulatory perspectives of
validation illustrate the usual issues facing teams wishing
to validate methods (in particular, quite why validation is a
laborious process), a perspective emerged that perhaps starts
to illustrate a different issue that ALI in vitro modeling tech-
nology may face—the question of what to validate.
The setting for validation studies might vary widely be-
cause different user groups have different endpoint aims.
From a regulatory perspective, a method should be able to
predict likely endpoints that are relevant to human health
(and particularly safety, from a regulatory point of view).
In that broad sense, there is a need to demonstrate that a
method delivers in terms of relevance, applicability, repeat-
ability, reproducibility, transferability, and predictive capac-
ity. From a regulatory perspective that might well make
sense and indeed that is the overall method that is used to val-
idate methods.
However, from a research perspective, the case is differ-
ent. The key aim here, in theory, is that an in vitro method
represents the human in vivo situation as closely as possible.
The conclusions of experiments using in vitro methods
should after all be representative of what happens in humans
and be predictive of outcomes.
Unfortunately that is not the case. In many cases, as was
demonstrated at the workshop, the level of validation with
respect to inhalation toxicology methods and particularly
ALI approaches was small to nonexistent. Particularly
from the perspective of research, the level of validation of
methods was minimal, as reported by the participants at
the workshop.
From the discussions (which are extensively reported in
the Supplementary Data), several key points have been raised
by the experts to consider regarding the validation of ALI
methods for mimicking inhalation toxicology endpoints.
The first issue that was pointed out is that at the present
time, nobody knows what models to develop in terms of val-
idation and even whether it is realistic to expect that a limited
number of models can ever adequately provide solutions for
inhalation toxicology endpoints. In other words, the basic
question is ‘‘validation is fine and needed, but what should
be validated?’’ Considering the sheer number of endpoints,
it seems unrealistic to expect one model would ever be suf-
ficient for either regulatory assessments or research and that
it was more likely that a series of methods would be needed.
These might focus on specific local and systemic effects or
on specific endpoints such as irritation, inflammation, carci-
nogenesis, fibrosis, or sensitization. There is a pressing need
to catalog currently available methods and to then ask what is
needed soon to answer the most pressing research questions.
There is currently no real toolbox of approaches available
and therefore nothing to actually validate.
Key points
 Numerous endpoints means it is unrealistic to expect
one or a small number of methods will be sufficient to
adequately assess all inhalation toxicology endpoints.
 No catalog available of research methods currently and
no real list of the most pressing research questions make
deciding on what to validate hard to answer.
 Agreement on a widely accepted standard to benchmark
methods could be a useful tool for the community.
The second highlighted issue was a critical lack of stan-
dardization between groups in the field, which means com-
paring experimental outcomes is often difficult. There are
still many open questions relating to these systems and ap-
proaches, not least from the perspective of validation. In a
regulatory perspective, a wider demand for validated inhala-
tion toxicology in vitro methods was highlighted with the
general points being that the area is of high interest for gov-
ernments and that in fact new EU legislation will mean much
better methods will be needed for assessing a variety of end-
points in the near future.
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Key points
 Lack of validation and standardization in the field
makes comparing experimental outcomes difficult.
 Validation is one of many open questions relating to
ALI systems.
 There is a general demand for relevant validated methods.
One of the more striking issues to arise in the discussions
related to in vivo human relevance of methods. This issue
was clearly highlighted suggesting that methods should ide-
ally represent real human outcomes but that currently, refer-
ence points for inhalation toxicology are weak to nonexistent
with little human data to go on. Certain approaches to im-
prove this situation were proposed, including the use of epi-
demiological data possibly from occupational environments.
The fact was highlighted that some in vitro methods
are only benchmarked against animal data and, in certain
cases, these data are historic and of questionable quality
given new data that have since emerged.
Key points
 Human relevance of models is essential, with validation
taking place against human data.
 Little human data available to actually benchmark val-
idation outcomes.
 Historic (animal) data may be of questionable quality.
Recommendations
While it was clear that validation of inhalation toxicology
methods and especially ALI models face many hurdles, a
number of suggestions did emerge on a possible route for-
ward. As mentioned already, standardization of approaches
should be a key step to address many of the issues raised
above. In particular, it was suggested that, however, many
methods are needed to assess the endpoints desired, it was cru-
cial that they are comparable between users. However, agree-
ing on what to validate remained a key issue. Especially for
regulators, it appeared important and much needed to set pri-
orities as a first step. A number speculated that because of the
diversity of methods available it was possible that there are
simply too many options available for anyone to agree on
where to start. It may also be the case that the field has devel-
oped in a fragmented manner and simply that validation has
not been a priority (yet) of many of the researchers actively de-
veloping methods. However, given the evidence of clear lines
of demand for validation in the field, it was recognized that it
was now important to get started on the process as a priority.
To push ahead in this direction, some recommendations
have emerged during the discussions (Fig. 4).
Strategic recommendations
Considering the clear hurdles in starting such a process,
the first recommendation is to organize a network to define
FIG. 4. Initiation of the
validation process for the use
of ALI systems in the field
of respiratory toxicology.
EURL ECVAM, European
Union Reference Laboratory
for alternatives to animal
testing.
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strategy, combine previously available information, and to
define and execute trials to start the validation process. It is
recommended to:
(1) Set up a dissemination strategy, including website, for
exchange of methods and technology,
(2) organize a specific scientific event such as a workshop
or meeting on a regular basis,
(3) categorize diverse methods and topics to define an ini-
tial direction of validation [such as ‘‘acute toxicity
testing’’ or ‘‘(nano)-aerosols’’ or ‘‘efficacy testing in
pharmacology’’], and
(4) implement technical recommendations such as those
below to define a first common level of ‘‘good
in vitro inhalation praxis.’’
Technical recommendations
One future challenge will be to find an appropriate strategy
to guide the diversity of methods and applications into the di-
rection of harmonization and standardization. This involves
the biological test system, the exposure design, and the
choice and implementation of cellular readouts at the same
level of importance.
With regard to the exposure design, two principle ways
may be present. One way may be the definition of a single
validated setup involving procedures and equipment for gen-
eration and characterization of exposure atmospheres and
exposures of a limited number of biological test systems.
The other way could be a definition of process parameters
for any setup to be defined and used in such an approach.
Since the latter represents a more open harmonization and
standardization strategy applicable to the constantly growing
number of new applications and strategies, this would result
in a living and growing number of documents that would
have a higher acceptance from users. Briefly, it would in-
clude the definition of process parameters such as quality,
performance, and validation criteria for all components of
the in vitro experimental design. This would include the
following:
(1) The generation and characterization of the test atmo-
spheres.
(2) The characterization of the cellular exposure, the bio-
logical test system, and the readouts applied.
(3) And, last but not least, a clear documentation of all ex-
perimental parameters and outcomes (with respect
to test atmospheres, exposure, biological test system,
and readouts).
On the one hand, the focus of these criteria would be tech-
nical performance criteria (i.e., technical/physical/chemical
criteria), but also biological performance criteria that are
strongly related to individual applications are necessary.
They should include the following:
(4) Clearly defined control situations (positive and nega-
tive controls), which in the best case should be selected
based on human data to establish a good control in the
direction of translation from the in vivo to the in vitro
situation.
Such a strategy for harmonization/standardization in the
field of cell-based in vitro inhalation sciences could be the
basis for further development, as it is urgently needed as
an alternative method also in the sense of the 3Rs.
Scientific recommendations
ALI methods are for many reasons considered to be more
advanced than classic (i.e., submerged) in vitro exposure
methods. Nevertheless, the final point for validation of ALI
methodologies will be to define clear situations where
ALI methods should be used instead or in support of animal
experimentations or classic in vitro methods. This is a pre-
requisite for the use of ALI methods in a regulatory purpose.
Defining clear situations would require the following:
(a) Comparison studies between ALI and animal experi-
mentation and/or human data if available.
(b) Comparison studies between ALI methods and classic
in vitro methods.
Some comparison studies have been performed recently,
between ALI and classic submerged experiments. Neverthe-
less, few in vitro comparisons data are available. In vivo,
no clear comparison data with ALI are available yet in the
literature, although some comparison studies have been per-
formed between in vivo and in vitro using classic submerged
conditions. At this moment, it is thus not yet possible to de-
fine clearly when ALI methods should be recommended and
there is an urgent need for more comparison studies, in par-
ticular between the ‘‘ALI’’ and the in vivo.
To generate reliable comparison data between in vivo/
ALI/classic in vitro, it is recommended:
(1) To use cell models representative of the target tissue
in vivo.
(2) To measure the exposure doses and to use relevant and
comparable dose metrics.
(3) To use similar endpoints.
(4) To perform similar statistical comparisons.
Conclusion
The development of ALI approaches to assess inhalation
toxicology endpoints continues apace. Many of these ad-
vances were highlighted in the workshop and there was a
general expectation that developments will continue, partic-
ularly in collaborative research projects. It was recognized
by all that the significance and relevance of data from ALI
strategies, although not validated until now, are expected
to be a key strategy for establishment of alternative methods
in inhalation toxicology and research.
However, it became clear that key questions remain in re-
lation to a number of issues and particularly validation.
Demand for validated methods remains high among aca-
demic, industrial, and regulatory organizations, although
for strikingly different reasons.
The numerous endpoints that can be tested in inhalation
toxicology mean that a considerable diversity of methods
has emerged. When considered in the light of validation,
the seemingly simple question of what to validate emerged
as a key concern of many workshop participants. The rel-
evance of methods, particularly in relation to reality in hu-
mans, was also highlighted as an issue that should be
addressed particularly as new methods develop. While
many agreed on the necessity of validation, the process
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was not immediately apparent. To assist the process, a gen-
eral introduction to validation was given by speakers with
experience in the area. Through this it became clear that
priority setting was needed and subsequently that a net-
work be established to achieve this and to subsequently de-
sign and run validation studies in the area.
To conclude, the workshop brought together key experts
and users of ALI models to discuss developments in the
area, and consider the question of how to start a process of
validation. Recommendations included the establishment of
a network to ensure validation commences in the area.
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